Literature DB >> 16424013

Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human.

Naoki Morito1, Keigyou Yoh, Yuki Fujioka, Takako Nakano, Homare Shimohata, Yuko Hashimoto, Akiko Yamada, Atsuko Maeda, Fumihiko Matsuno, Hiroyuki Hata, Atsushi Suzuki, Shigehiko Imagawa, Hiroaki Mitsuya, Hiroyasu Esumi, Akio Koyama, Masayuki Yamamoto, Naoyoshi Mori, Satoru Takahashi.   

Abstract

c-Maf translocation or overexpression has been observed in human multiple myeloma. Although c-maf might function as an oncogene in multiple myeloma, a role for this gene in other cancers has not been shown. In this study, we have found that mice transgenic for c-Maf whose expression was direct to the T-cell compartment developed T-cell lymphoma. Moreover, we showed that cyclin D2, integrin beta(7), and ARK5 were up-regulated in c-Maf transgenic lymphoma cells. Furthermore, 60% of human T-cell lymphomas (11 of 18 cases), classified as angioimmunoblastic T-cell lymphoma, were found to express c-Maf. These results suggest that c-Maf might cause a type of T-cell lymphoma in both mice and humans and that ARK5, in addition to cyclin D2 and integrin beta(7), might be downstream target genes of c-Maf leading to malignant transformation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424013     DOI: 10.1158/0008-5472.CAN-05-2154

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  ARK5 is associated with the invasive and metastatic potential of human breast cancer cells.

Authors:  Xin-Zhong Chang; Jie Yu; Hai-Yin Liu; Rui-Hua Dong; Xu-Chen Cao
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

2.  Extranodal Marginal Zone Lymphoma-like Presentations of Angioimmunoblastic T-Cell Lymphoma: A T-Cell Lymphoma Masquerading as a B-Cell Lymphoproliferative Disorder.

Authors:  Benjamin Kaffenberger; Brad Haverkos; Kelly Tyler; Henry K Wong; Pierluigi Porcu; Alejandro Ariel Gru
Journal:  Am J Dermatopathol       Date:  2015-08       Impact factor: 1.533

3.  Transgene insertion in proximity to the c-myb gene disrupts erythroid-megakaryocytic lineage bifurcation.

Authors:  Harumi Y Mukai; Hozumi Motohashi; Osamu Ohneda; Norio Suzuki; Masumi Nagano; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2006-08-28       Impact factor: 4.272

4.  Phosphorylation within the MafA N terminus regulates C-terminal dimerization and DNA binding.

Authors:  Shuangli Guo; Nathan L Vanderford; Roland Stein
Journal:  J Biol Chem       Date:  2010-03-05       Impact factor: 5.157

Review 5.  Interleukin-21: a double-edged sword with therapeutic potential.

Authors:  Rosanne Spolski; Warren J Leonard
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

6.  MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.

Authors:  Ya-Wei Qiang; Shiqiao Ye; Yu Chen; Amy F Buros; Ricky Edmonson; Frits van Rhee; Bart Barlogie; Joshua Epstein; Gareth J Morgan; Faith E Davies
Journal:  Blood       Date:  2016-10-28       Impact factor: 22.113

Review 7.  The differential expression of IL-4 and IL-13 and its impact on type-2 immunity.

Authors:  Katherine Bao; R Lee Reinhardt
Journal:  Cytokine       Date:  2015-06-11       Impact factor: 3.861

8.  Ribozyme-mediated targeting of IkappaBgamma inhibits melanoma invasion and metastasis.

Authors:  Sima Z Torabian; David de Semir; Mehdi Nosrati; Sepideh Bagheri; Altaf A Dar; Sylvia Fong; Yong Liu; Scot Federman; Jeff Simko; Chris Haqq; Robert J Debs; Mohammed Kashani-Sabet
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

9.  Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB.

Authors:  Carolina Vicente-Dueñas; Inés González-Herrero; María Begoña García Cenador; Francisco Javier García Criado; Isidro Sánchez-García
Journal:  Cell Cycle       Date:  2012-09-14       Impact factor: 4.534

Review 10.  The aryl hydrocarbon receptor (AhR) pathway as a regulatory pathway for cell adhesion and matrix metabolism.

Authors:  Tiffany Kung; K A Murphy; L A White
Journal:  Biochem Pharmacol       Date:  2008-10-01       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.